These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 14045304)

  • 1. EFFECT OF TRISODIUM CALCIUM DIETHYLENETRIAMINEPENTAACETATE ON BIVALENT CATIONS IN THALASSEMIA MAJOR.
    MULLER-EBERHARD U; ERLANDSON ME; GINN HE; SMITH CH
    Blood; 1963 Aug; 22():209-17. PubMed ID: 14045304
    [No Abstract]   [Full Text] [Related]  

  • 2. BIVALENT CATIONS IN HOMOZYGOUS THALASSEMIA.
    ERLANDSON ME; GOLUBOW J; WEHMAN J; SMITH CH
    J Pediatr; 1965 Mar; 66():637-48. PubMed ID: 14264319
    [No Abstract]   [Full Text] [Related]  

  • 3. METABOLISM OF IRON, CALCIUM AND MAGNESIUM IN HOMOZYGOUS THALASSEMIA.
    ERLANDSON ME; GOLUBOW J; WEHMAN J; SMITH CH
    Ann N Y Acad Sci; 1964 Oct; 119():769-75. PubMed ID: 14219456
    [No Abstract]   [Full Text] [Related]  

  • 4. FACTORS INFLUENCING THE CLINICAL USE OF CHELATES IN IRON STORAGE DISEASE.
    WEINER M
    Ann N Y Acad Sci; 1964 Oct; 119():789-96. PubMed ID: 14219458
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium, Magnesium, Calcium, Manganese, Iron, Copper, and Zinc in Serums of Beta Thalassemia Major Patients.
    Şahin A; Er EÖ; Öz E; Yıldırmak ZY; Bakırdere S
    Biol Trace Elem Res; 2021 Mar; 199(3):888-894. PubMed ID: 32462603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THE ASSOCIATION OF HEMOCHROMATOSIS WITH THALASSEMIA MINOR.
    LEWIS M; LEE GR; HAUT A
    Ann Intern Med; 1965 Jul; 63():122-8. PubMed ID: 14305959
    [No Abstract]   [Full Text] [Related]  

  • 7. [THE USE OF DESFERRIOXAMINE IN THE TREATMENT OF HEMOCHROMATOSIS].
    CARLOS AG; SOARES AD
    J Med (Oporto); 1964 Apr; 53():1021-32. PubMed ID: 14145895
    [No Abstract]   [Full Text] [Related]  

  • 8. BIOCHEMICAL STUDIES IN THALASSEMIA.
    PRASAD AS; DIWANY M; GABR M; SANDSTEAD HH; MOKHTAR N; HEFNY AE
    Ann Intern Med; 1965 Jan; 62():87-96. PubMed ID: 14258353
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of trisodium calcium diethylenetriaminepentacetate in iron storage disease.
    FAHEY JL; RATH CE; PRINCIOTTO JV; BRICK IB; RUBIN M
    J Lab Clin Med; 1961 Mar; 57():436-49. PubMed ID: 13697901
    [No Abstract]   [Full Text] [Related]  

  • 10. [Metabolism of iron and copper, action of chelators and therapeutic possibilities in Wilson's disease and hemochromatosis].
    PIRART J
    Pathol Biol; 1961 May; 9():1157-74. PubMed ID: 13735975
    [No Abstract]   [Full Text] [Related]  

  • 11. IDIOPATHIC HAEMOCHROMATOSIS IN MENSTRUATING WOMEN. A FAMILY STUDY, INCLUDING THE USE OF DIETHYLENE TRIAMINE PENTA-ACETIC ACID.
    LLOYD HM; POWELL LW; THOMAS MJ
    Lancet; 1964 Sep; 2(7359):555-7. PubMed ID: 14172348
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron excretion in thalassaemia major after administration of chelating agents.
    SMITH RS
    Br Med J; 1962 Dec; 2(5319):1577-80. PubMed ID: 13989576
    [No Abstract]   [Full Text] [Related]  

  • 13. Type 3 hemochromatosis and beta-thalassemia trait.
    Riva A; Mariani R; Bovo G; Pelucchi S; Arosio C; Salvioni A; Vergani A; Piperno A
    Eur J Haematol; 2004 May; 72(5):370-4. PubMed ID: 15059075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRON METABOLISM IN SYMPTOMATIC PORPHYRIA. A PRELIMINARY COMMUNICATION.
    SAUNDERS SJ
    S Afr J Lab Clin Med; 1963 Dec; 14():277-82. PubMed ID: 14110525
    [No Abstract]   [Full Text] [Related]  

  • 15. Percutaneous excretion of iron and ferritin (through Al-hijamah) as a novel treatment for iron overload in beta-thalassemia major, hemochromatosis and sideroblastic anemia.
    El Sayed SM; Abou-Taleb A; Mahmoud HS; Baghdadi H; Maria RA; Ahmed NS; Nabo MM
    Med Hypotheses; 2014 Aug; 83(2):238-46. PubMed ID: 24857772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ; Spyrou A; Kolnagou A
    Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterozygosity for the H63D mutation in the hereditary hemochromatosis (HFE) gene may lead into severe iron overload in beta-thalassemia minor: observations in a thalassemic kindred.
    Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Sánchez-Anzaldo J; Ruiz-Delgado GJ; Jiménez-González C; Carrera B
    Rev Invest Clin; 2001; 53(2):117-20. PubMed ID: 11421105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Disease caused by iron overload associated to minor beta thalassemia].
    García Pont J; Moreu Araño I; Asensio Montoro A; Rueda García A
    An Med Interna; 1993 Apr; 10(4):203. PubMed ID: 8513091
    [No Abstract]   [Full Text] [Related]  

  • 19. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251-264].
    Nick HP
    Hemoglobin; 2011; 35(2):175-9. PubMed ID: 21417578
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of portable X-ray fluorescence (PXRF) in vivo as an alternative technique for the assessment of iron levels in patients with thalassemia and hemochromatosis.
    Estevam M; Appoloni CR
    Health Phys; 2013 Feb; 104(2):132-8. PubMed ID: 23274815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.